ArticleGynecologic oncology2019
Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women.
Open access · greenAbstract read
In one paragraph
Article in Gynecologic oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 48 citations in OpenAlex.
- Review
- Large-scale integration of omics and electronic health records to identify potential risk protein biomarkers and therapeutic drugs for cancer prevention.American journal of human genetics · 2026Article
- Vestibulodynia presentation is differentiated by the presence of additional chronic primary pain conditions.The journal of pain · 2025Article
- Optimization of multi-ancestry polygenic risk score disease prediction models.Scientific reports · 2025Article
- Single nucleotide polymorphisms in ovarian cancer impacting lipid metabolism and prognosis: an integrated TCGA database analysis.BMC cancer · 2025Article
- ETS-1 in tumor immunology: implications for novel anti-cancer strategies.Frontiers in immunology · 2025Review
- Association ofGynecology and pelvic medicine · 2025Article
- SUGT1 regulates the progression of ovarian cancer through the AKT/PI3K/mTOR signaling pathway.Translational oncology · 2024Article
- Integrating muti-omics data to identify tissue-specific DNA methylation biomarkers for cancer risk.Nature communications · 2024Article
- Article
- Hidden secrets of the cancer genome: unlocking the impact of non-coding mutations in gene regulatory elements.Cellular and molecular life sciences : CMLS · 2024Review
- Cis- and trans-eQTL TWASs of breast and ovarian cancer identify more than 100 susceptibility genes in the BCAC and OCAC consortia.American journal of human genetics · 2024Article
- Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions.American journal of human genetics · 2024Article
- Fine-scale mapping of chromosome 9q22.33 identifies candidate causal variant in ovarian cancer.PeerJ · 2024Article
- Association ofmedRxiv : the preprint server for health sciences · 2023Article
- Article
- Design and quality control of large-scale two-sample Mendelian randomization studies.International journal of epidemiology · 2023Article
- Understanding How Pregnancy Protects Against Ovarian and Endometrial Cancer Development: Fetal Antigens May Be Involved.Endocrinology · 2022Review
- Genome-Wide Association Study of Fluorescent Oxidation Products Accounting for Tobacco Smoking Status in Adults from the French EGEA Study.Antioxidants (Basel, Switzerland) · 2022Article
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk.European journal of human genetics : EJHG · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
53 authors at 20 institutions in 10 countries.
Kate LawrensonWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Suite 290W, Los Angeles, CA, USA; Center for Bioinformatics and Functional Genomics, Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: kate.lawrenson@cshs.org.
Fengju SongNational Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Epidemiology and Biostatistics, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Dennis J HazelettCenter for Bioinformatics and Functional Genomics, Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Siddhartha P KarDepartment of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
Jonathan TyrerDepartment of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
Catherine M PhelanDepartment of Gynecologic Oncology, Moffitt Cancer Center, Tampa, FL, USA; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
Rosario I CoronaWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Suite 290W, Los Angeles, CA, USA; Center for Bioinformatics and Functional Genomics, Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Norma I Rodríguez-MalavéCenter for Bioinformatics and Functional Genomics, Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Ji-Hei SeoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Emily AdlerDepartment of Preventive Medicine, University of Southern California, Keck School of Medicine, 1450 Biggy Street, Los Angeles, CA, USA.
Simon G CoetzeeCenter for Bioinformatics and Functional Genomics, Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Felipe SegatoDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo, 14049-900, Brazil.
Marcos A S FonsecaDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo, 14049-900, Brazil.
Christopher I AmosInstitute for Clinical and Translational Research, Department of Medicine, Baylor School of Medicine, Houston,TX, USA.
Michael E CarneyDepartment of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.
Georgia Chenevix-TrenchGenetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia.
Jiyeob ChoiDepartment of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea; Department of Biomedical Science, Graduate School, Seoul National University, Seoul, Republic of Korea.
Jennifer A DohertyJon M. and Karen Huntsman Endowed Associate Professor in Cancer Research Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, USA.
Weihua JiaState Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, China.
Gang J JinShanghaiBio Corporation, Shanghai, China; CloudHealth Genomics Ltd, Shanghai, China.
Byoung-Gie KimDepartment of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University, School of Medicine, Republic of Korea.
Nhu D LeCancer Control Research, BC Cancer Agency, Vancouver, BC, Canada.
Juyeon LeeDepartment of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Biomedical Science, Graduate School, Seoul National University, 103 Daehak-ro, Jongno-gu, Seoul 110-799, Republic of Korea.
Lian LiNational Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Epidemiology and Biostatistics, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Boon K LimThe Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Noor A AdenanThe Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Mika MizunoDepartment of Gynecological Oncology, Aichi Cancer Center Hospital, Japan.
Boyoung ParkDepartment of Preventive Medicine, College of Medicine, Hanyang, Seoul, Republic of Korea.
Celeste L PearceDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Kang ShanDepartment of Obstetrics and Gynaecology,Hebei Medical University, Fourth Hospital, Shijiazhuang, China.
Yongyong ShiBio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China.
Xiao-Ou ShuDivision of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
Weiva SiehDepartment of Population Health Science and Policy, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Australian Ovarian Cancer Study GroupPeter MacCallum Cancer Institute, Melbourne, Australia.
Pamela J ThompsonCancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Lynne R WilkensCancer Epidemiology Program, University of Hawaii Cancer Center, HI, USA.
Qingyi WeiCancer Institute, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA.
Yin L WooThe Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Li YanDepartment of Molecular Biology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China.
Beth Y KarlanWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Suite 290W, Los Angeles, CA, USA.
Matthew L FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Houtan NoushmehrDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo, 14049-900, Brazil; Department of Neurosurgery, Henry Ford Health System, Detroit, MI, USA.
Ellen L GoodeDepartment of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
Andrew BerchuckDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA.
Thomas A SellersDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
Soo-Hwang TeoCancer Research Initiatives Foundation, Subang Jaya, Selangor, Malaysia.
Wei ZhengDivision of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
Keitaro MatsuoDivision of Molecular and Clinical Epidemiology, Aichi Cancer Center Research Institute, Japan.
Sue ParkDepartment of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea; Department of Biomedical Science, Graduate School, Seoul National University, Seoul, Republic of Korea.
Kexin ChenNational Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Epidemiology and Biostatistics, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Paul D P PharoahDepartment of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge, UK.
Simon A GaytherCenter for Bioinformatics and Functional Genomics, Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Marc T GoodmanCancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Cedars-Sinai Medical Center · USNew Generation University College · ETTianjin Medical University Cancer Institute and Hospital · CNUniversity of Malaya · MYAichi Cancer Center · JPDana-Farber Cancer Institute · USHebei Medical University · CNMoffitt Cancer Center · USUniversidade de São Paulo · BRUniversity of Cambridge · GBUniversity of Hawaiʻi at Mānoa · USVanderbilt University · USBaylor School · USBC Cancer Agency · CACancer Research Malaysia · MYDuke Medical Center · USFudan University Shanghai Cancer Center · CNHanyang University · KRHenry Ford Health System · USHuntsman Cancer Institute · US
Funding
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MUCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1MTwo-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5MStatistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8MUCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0MUniversity of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026
$56.2MThe Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · 2005 to 2026
$49.9MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MUnderstanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0MCancer Research UK 10119Cancer Research UK 10124Cancer Research UK 14136Cancer Research UK 16561Cancer Research UK C12292/A11174Cancer Research UK C1287/A10118Cancer Research UK C1287/A10710Cancer Research UK C490/A10119Cancer Research UK C490/A10124Cancer Research UK C490/A8339Cancer Research UK C570/A16491Cancer Research UK C8221/A19170Department of HealthIntramural NIH HHS Z01 ES044005Medical Research Council 1000143Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MR/M012190/1Medical Research Council MR/N003284/1NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR001881NCI NIH HHS K07 CA080668NCI NIH HHS N01 CN025403NCI NIH HHS N01 PC067010NCI NIH HHS P01 CA017054NCI NIH HHS P01 CA087969NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA071789NCI NIH HHS P30 CA076292NCI NIH HHS P50 CA105009NCI NIH HHS P50 CA116201NCI NIH HHS P50 CA136393NCI NIH HHS P50 CA159981NCI NIH HHS R00 CA184415NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA054281NCI NIH HHS R01 CA054419NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA058860NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA063678NCI NIH HHS R01 CA063682NCI NIH HHS R01 CA067262NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA095023NCI NIH HHS R01 CA112523NCI NIH HHS R01 CA114343NCI NIH HHS R01 CA116167NCI NIH HHS R01 CA122443NCI NIH HHS R01 CA126841NCI NIH HHS R01 CA128978NCI NIH HHS R01 CA141154NCI NIH HHS R01 CA149429NCI NIH HHS R01 CA160669NCI NIH HHS R01 CA176785NCI NIH HHS R01 CA211707NCI NIH HHS R03 CA113148NCI NIH HHS R03 CA115195NCI NIH HHS R21 CA220078NCI NIH HHS U01 CA069417NCI NIH HHS U01 CA116167NCI NIH HHS U01 CA164973NCI NIH HHS U19 CA148065NCI NIH HHS U19 CA148112NCI NIH HHS U19 CA148537NCI NIH HHS UM1 CA176726NCI NIH HHS UM1 CA182910NCI NIH HHS UM1 CA186107NCRR NIH HHS M01 RR000056NCRR NIH HHS S10 RR025141NIA NIH HHS R01 AG061132Wellcome TrustWellcome Trust 076113
Abstract
objectiveGenome-wide association studies (GWASs) for epithelial ovarian cancer (EOC) have focused largely on populations of European ancestry. We aimed to identify common germline variants associated with EOC risk in Asian women.
methodsGenotyping was performed as part of the OncoArray project. Samples with >60% Asian ancestry were included in the analysis. Genotyping was performed on 533,631 SNPs in 3238 Asian subjects diagnosed with invasive or borderline EOC and 4083 unaffected controls. After imputation, genotypes were available for 11,595,112 SNPs to identify associations.
resultsAt chromosome 6p25.2, SNP rs7748275 was associated with risk of serous EOC (odds ratio [OR] = 1.34, P = 8.7 × 10
conclusionWhile some risk loci were shared between East Asian and European populations, others were population-specific, indicating that the landscape of EOC risk in Asian women has both shared and unique features compared to women of European ancestry.
Indexed as
Asian PeopleBase SequenceCarcinoma, Ovarian EpithelialCase-Control StudiesFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansPolymorphism, Single NucleotideQuantitative Trait LociAsian ancestryEnhancerEpithelial ovarian cancereQTLGene regulationGenome-wide association study
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.